<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00148148</url>
  </required_header>
  <id_info>
    <org_study_id>KKS-MS-005-KMT-10/03</org_study_id>
    <secondary_id>BfArM 4021825</secondary_id>
    <nct_id>NCT00148148</nct_id>
  </id_info>
  <brief_title>A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell Transplantation</brief_title>
  <official_title>Phase II Randomised Study of the Safety, Efficacy and Pharmacokinetics of Caspofungin (CAS), Liposomal Amphotericin B (LAMB) or the Combination of Caspofungin With Liposomal Amphotericin B for Patients After Stem-Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <brief_summary>
    <textblock>
      The study compares the safety, efficacy and pharmacokinetics of caspofungin, liposomal&#xD;
      amphotericin B or the combination of both in the antifungal treatment of adult patients after&#xD;
      allogeneic haematopoietic stem-cell transplantation with granulocytopenia and persistent i.g.&#xD;
      recurrent fever under adequate antibacterial therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open, randomised, three-arm multicenter phase II clinical trial investigating the&#xD;
      safety, tolerance and plasma pharmacokinetics of caspofungin, liposomal amphotericin B and&#xD;
      the combination of both agents as empirical antifungal therapy in adult patients following&#xD;
      allogeneic hematopoietic stem cell transplantation.&#xD;
&#xD;
      Eligible patients are those with profound granulocytopenia (≤ 500 neutrophil granulocytes)&#xD;
      and persistent or recurrent fever despite broad-spectrum antibacterial therapy of a minimum&#xD;
      of 36-48 hours duration. Patients are stratified according to the type of the transplantation&#xD;
      (human leukocyte antigen [HLA] matched/related versus HLA-mismatched/unrelated) and&#xD;
      randomized into one of the following treatment arms: Caspofungin alone (50 mg/day with a&#xD;
      loading dose of 70 mg on day 1), liposomal amphotericin B alone (3 mg/kg/day), or the&#xD;
      combination of caspofungin and liposomal amphotericin B (similar dosages as in the&#xD;
      single-drug treatment arms).&#xD;
&#xD;
      Caspofungin and liposomal amphotericin B are administered once daily as an intravenous&#xD;
      infusion. Serial plasma samples for determination of pharmacokinetic parameters are collected&#xD;
      on days one and four of treatment. Safety and tolerance of the randomised intervention are&#xD;
      evaluated daily, following the last dose of study drug and at 14 days after last dose of&#xD;
      study drug according to current NCI-CTC criteria. Antifungal efficacy and survival are&#xD;
      evaluated following the last dose of study drug and at 14 days after the last dose of study&#xD;
      drug.&#xD;
&#xD;
      Treatment with study drug is continued until either:&#xD;
&#xD;
        1. treatment limiting intolerance or toxicity;&#xD;
&#xD;
        2. hematopoietic engraftment (≥ 500 neutrophil granulocytes on three consecutive days) and&#xD;
           defervescence; or&#xD;
&#xD;
        3. the occurrence of a probable or proven invasive fungal infection using current EORTC/MSG&#xD;
           criteria.&#xD;
&#xD;
      Febrile granulocytopenic patients with probable or proven invasive fungal infections are not&#xD;
      eligible for this study. Patients who develop a probable or proven breakthrough infection are&#xD;
      taken off study and receive standard therapy. Breakthrough infections are defined as probable&#xD;
      or proven invasive fungal infections that occur during treatment with study medication.&#xD;
&#xD;
      Twenty-five patients with a minimum duration of treatment of four days will be randomised per&#xD;
      study arm. Patients who receive at least one dose of study drug are eligible for analysis of&#xD;
      safety, tolerance and pharmacokinetics. For the analysis of the secondary endpoints of&#xD;
      antifungal efficacy and survival, two separate cohorts will be analysed. These include:&#xD;
&#xD;
        1. patients who received at least one dose of study drug; and&#xD;
&#xD;
        2. patients who received ≥ four doses of study drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date>December 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and efficacy of caspofungin, liposomal amphotericin B and the combination of caspofungin with liposomal amphotericin B in accordance with NCI-CTC toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics and recording of the dose-intensity of caspofungin and liposomal amphotericin B in the setting of allogeneic stem cell transplantation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examination of pharmacokinetical interactions between caspofungin and liposomal amphotericin B</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recording of the efficacy of caspofungin, liposomal amphotericin B and the combination of caspofungin and liposomal amphotericin B in the case of empirical antimycotic therapy</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <condition>Fungus Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caspofungin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal amphotericin B</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (&gt; or = 18 years of age) with granulocytopenia (absolute number of neutrophil&#xD;
             granulocytes [ANC]: &lt; or = 500/µL) who have undergone allogeneic haematopoeitic stem&#xD;
             cell transplantation and immunosuppression with cyclosporin A&#xD;
&#xD;
          -  Patients with persistent or recurrent fever (oral temperature &gt; or = 38.0°C) and&#xD;
             granulocytopenia (absolute neutrophil count &lt; or = 500/µL) and adequate antibacterial&#xD;
             therapy for &gt; or = 36-48 hours, who need empirical antimycotic therapy&#xD;
&#xD;
          -  Already inserted at least double-lumen central venous catheter for administration of&#xD;
             drugs and extraction of plasma samples&#xD;
&#xD;
          -  Sufficient renal and hepatic function&#xD;
&#xD;
          -  Availability of negative pregnancy test and adequate contraceptive measures for female&#xD;
             patients of childbearing age&#xD;
&#xD;
          -  Availability of written informed consent from the patient or respectively from the&#xD;
             legal representative after prior information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with active, possible or proven (MSG-EORTC criteria) invasive fungal&#xD;
             infection at time of enrollment&#xD;
&#xD;
          -  Pregnant or nursing patients&#xD;
&#xD;
          -  Patients with pathological functional renal or hepatic parameters&#xD;
&#xD;
          -  Patients with clinical or laboratory chemical evidence of active veno-occlusive&#xD;
             disease (VOD)&#xD;
&#xD;
          -  Hemodynamically unstable patients with a life expectancy of less than 5 days&#xD;
&#xD;
          -  Patients undergoing co-medication with rifampicin, phenytoin, carbamazepine,&#xD;
             phenobarbital, dexamethasone, efavirenz and nevirapine&#xD;
&#xD;
          -  Patients with prior known serious reaction to echinocandin-antifungal formulation or&#xD;
             documented allergy to amphotericin B&#xD;
&#xD;
          -  Patients with other condition or illness which, in the estimation of the investigator,&#xD;
             distorts the study results or leads to an additional risk for the patient&#xD;
&#xD;
          -  Prior inclusion in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Groll, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Muenster</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KKS Münster University Hospital</name>
      <address>
        <city>Münster</city>
        <state>NRW</state>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>January 9, 2008</last_update_submitted>
  <last_update_submitted_qc>January 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2008</last_update_posted>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Caspofungin</keyword>
  <keyword>Liposomal Amphotericin B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Caspofungin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

